Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    - Added a Locations section with Maryland as a study site. Updated the page revision from v3.3.2 to v3.3.3 and removed Maryland Locations and HHS Vulnerability Disclosure references.
    Difference
    0.2%
    Check dated 2025-12-23T21:12:51.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    47 days ago
    Change Detected
    Summary
    New meta information was added: Melanoma and a MedlinePlus Genetics related topic, plus a new Last Update Posted (Estimated) and Revision: v3.3.2 on 2025-11-20, and older meta entries Last Update Posted and Revision: v3.2.0 were removed on 2025-07-09/10. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-25T11:37:20.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The funding/status notice at the top of the page has been removed. All study details, eligibility criteria, contacts, and locations remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T07:17:21.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Related topics links for Melanoma and MedlinePlus Genetics were removed from the page. Core trial information remains unchanged.
    Difference
    0.1%
    Check dated 2025-11-11T02:59:05.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    Formatting and layout updates to the study details page were observed, with no changes to core study data such as eligibility criteria, endpoints, or enrollment information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:20:29.000Z thumbnail image
  9. Check
    91 days ago
    Change Detected
    Summary
    Added MedlinePlus Genetics topic: Melanoma.
    Difference
    0.1%
    Check dated 2025-10-13T08:46:16.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.